R
Ultragenyx Pharmaceutical
RARE
44.140
USD
-0.87
(-1.93%)
مفتوح الان
حجم التداول
974
الربح لكل سهم
0
العائد الربحي
0
P/E
-8
حجم السوق
5,060,790,583
الأخبار
العنوان: Ultragenyx Pharmaceutical
القطاع: Healthcare
الصناعة: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.